Vote Scores

Home / Companies / Forte Biosciences, Inc. / 19 Sep 2023

Meeting · year to 30 June 202428 filers reporting

Forte Biosciences, Inc.: meeting of 19 Sep 2023

Votes reported on Form N-PX, item by item

28 Form N-PX filers reported votes at the Forte Biosciences, Inc. meeting of 19 Sep 2023. Their records fall into 9 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.

foragainstabstain, withhold or otheramber tick: the portion cast against management

Items

1

DIRECTOR ELECTIONSIssuer

Director elections

4 nominees; 63.6% of reported votes for; 4 filers withheld from or voted against at least one nominee.

40 vote records from 7 filers. 0 of the 7 filers that marked the item either way voted against management.

42.9% for0.0% against57.1% other0.0% against management7 filers
2

DIRECTOR ELECTIONSSecurity holder

Director elections (nominees put forward by security holders)

4 nominees; 27.3% of reported votes for; 7 filers withheld from or voted against at least one nominee.

40 vote records from 7 filers. 0 of the 7 filers that marked the item either way voted against management.

0.0% for0.0% against100.0% other0.0% against management7 filers
3

SECTION 14A SAY-ON-PAY VOTESIssuer

Advisory vote on executive pay (say-on-pay)

62 vote records from 28 filers. 14 of the 22 filers that marked the item either way voted against management. 6 filers reported this item without a management mark.

64.3% for7.1% against28.6% other63.6% against management28 filers93.3% for4.0% against2.7% other17.1% against management4,601,518 reported shares
4

SECTION 14A SAY-ON-PAY VOTESIssuer

Frequency of the say-on-pay vote

one year: 17 filers; do not vote: 2 filers; three years: 2 filers; 3-yr: 1 filer; take no action: 1 filer; n/a: 1 filer.

62 vote records from 28 filers. 7 of the 22 filers that marked the item either way voted against management. 6 filers reported this item without a management mark.

0.0% for0.0% against100.0% other31.8% against management28 filers0.0% for0.0% against100.0% other20.4% against management4,601,518 reported shares
5

AUDIT-RELATEDIssuer

Audit-related items (auditor ratification)

20 vote records from 7 filers. 0 of the 3 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.

85.7% for0.0% against14.3% other0.0% against management7 filers99.9% for0.0% against0.1% other0.0% against management852,339 reported shares
6

COMPENSATIONIssuer

COMPENSATION: management items

Management items in this category are shown together; filers word and number them differently.

20 vote records from 7 filers. 0 of the 3 filers that marked the item either way voted against management. 4 filers reported this item without a management mark.

85.7% for0.0% against14.3% other0.0% against management7 filers99.9% for0.0% against0.1% other0.0% against management852,339 reported shares, counted once per item in this group
7

SHAREHOLDER RIGHTS AND DEFENSESSecurity holder

The approval of the shareholder proposal to amend the Company's amended and restated bylaws.

19 vote records from 7 filers. 5 of the 7 filers that marked the item either way voted against management.

14.3% for71.4% against14.3% other71.4% against management7 filers0.8% for99.1% against0.1% other24.6% against management852,339 reported shares
8

SHAREHOLDER RIGHTS AND DEFENSESSecurity holder

Shareholder proposal: SHAREHOLDER RIGHTS AND DEFENSES

19 vote records from 7 filers. 0 of the 7 filers that marked the item either way voted against management.

42.9% for42.9% against14.3% other0.0% against management7 filers23.8% for76.2% against0.1% other0.0% against management852,339 reported shares
9

Several categoriesSecurity holder

Shareholder proposals (not separable from the filings)

Filers described these proposals in wordings that could not be matched to one another, so they are shown together.

2 vote records from 1 filers. No filer marked a management recommendation, so no against-management figure is reported. 1 filer reported this item without a management mark.

0.0% for0.0% against100.0% other1 filers

How the largest families voted

Family1. Directors2. Directors3. Say-on-pay4. Pay-vote frequency5. Auditor7. Proposal8. Proposal
VanguardForAbstain or withholdForSplit or no vote *ForAgainstAgainst
BlackRock and iSharesForAbstain or withholdAgainst *Split or no vote *ForFor *Against
FidelitySplit or no voteSplit or no voteFor *Split or no voteForAgainst *For
State Street and SPDRNo reportNo reportForSplit or no vote *No reportNo reportNo report
Goldman SachsNo reportNo reportForSplit or no vote *No reportNo reportNo report
Northern Trust and FlexSharesNo reportNo reportSplit or no voteSplit or no voteNo reportNo reportNo report
Guggenheim and RydexSplit or no voteSplit or no voteFor *Split or no voteForAgainst *For
BNY MellonNo reportNo reportFor *Split or no voteNo reportNo reportNo report

* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.

Questions

How did large funds vote at the Forte Biosciences, Inc. meeting?

28 Form N-PX filers reported votes at the meeting of 19 Sep 2023. On say-on-pay, 14 of 22 voted against management (63.6%). 2 proposals from security holders could be told apart in the filings. The family table lists each of the largest families item by item.

Is this the meeting result?

No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Forte Biosciences, Inc. on Form 8-K.

Why are director elections shown as counts only?

Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.

Every meeting on file for Forte Biosciences, Inc.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Forte Biosciences, Inc. with a meeting date within three days of 19 Sep 2023. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.